- Home
- CISS vs MBIO Comparison
CISS vs MBIO Comparison
Compare CISS & MBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CISS
- MBIO
- Stock Information
- Founded
- CISS 2022
- MBIO 2015
- Country
- CISS Greece
- MBIO United States
- Employees
- CISS N/A
- MBIO N/A
- Industry
- CISS Marine Transportation
- MBIO Biotechnology: Pharmaceutical Preparations
- Sector
- CISS Consumer Discretionary
- MBIO Health Care
- Exchange
- CISS Nasdaq
- MBIO Nasdaq
- Market Cap
- CISS 5.3M
- MBIO 4.7M
- IPO Year
- CISS N/A
- MBIO N/A
- Fundamental
- Price
- CISS $1.69
- MBIO $1.22
- Analyst Decision
- CISS
- MBIO
- Analyst Count
- CISS 0
- MBIO 0
- Target Price
- CISS N/A
- MBIO N/A
- AVG Volume (30 Days)
- CISS 114.8K
- MBIO 81.7K
- Earning Date
- CISS 11-18-2025
- MBIO 11-07-2025
- Dividend Yield
- CISS N/A
- MBIO N/A
- EPS Growth
- CISS N/A
- MBIO N/A
- EPS
- CISS N/A
- MBIO N/A
- Revenue
- CISS $33,613,149.00
- MBIO N/A
- Revenue This Year
- CISS N/A
- MBIO N/A
- Revenue Next Year
- CISS N/A
- MBIO N/A
- P/E Ratio
- CISS $0.29
- MBIO N/A
- Revenue Growth
- CISS N/A
- MBIO N/A
- 52 Week Low
- CISS $1.57
- MBIO $0.89
- 52 Week High
- CISS $17.25
- MBIO $21.95
- Technical
- Relative Strength Index (RSI)
- CISS 31.49
- MBIO 35.63
- Support Level
- CISS $1.57
- MBIO $1.14
- Resistance Level
- CISS $2.02
- MBIO $1.27
- Average True Range (ATR)
- CISS 0.14
- MBIO 0.09
- MACD
- CISS -0.03
- MBIO -0.01
- Stochastic Oscillator
- CISS 9.45
- MBIO 20.23
About CISS C3is Inc.
C3is Inc is a provider of international seaborne transportation services to dry bulk charterers, including major national and private industrial users, commodity producers and traders. The company owns and operates a fleet of two dry bulk carriers that transport major bulks such as iron ore, coal and grains, and minor bulks such as bauxite, phosphate and fertilizers. The total cargo-carrying capacity of its fleet is approximately 64,000 dwt.
About MBIO Mustang Bio Inc.
Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapy into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.